Atherosclerosis
Volume 205, Issue 1 , Pages 272-278 , July 2009

Risk factor correlates of platelet and leukocyte markers assessed by flow cytometry in a population-based sample

  • Aaron R. Folsom

      Affiliations

    • Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, 1300 South Second Street, Suite 300, Minneapolis, MN 55454-1015, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 612 626 8862 fax: +1 612 624 0315.
    • ,
  • Nena Aleksic

      Affiliations

    • Division of Hematology, University of Texas Health Science Center, Houston, TX, USA
    • ,
  • Antonio Sanhueza

      Affiliations

    • Collaborative Studies Coordinating Center, Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • ,
  • Eric Boerwinkle

      Affiliations

    • Human Genetics Center and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, USA

Received 30 April 2008 ,Revised 6 November 2008 ,Accepted 11 November 2008.

References 

  1. Wu KK. Platelet activation and arterial thrombosis. Lancet. 1994;344:991–995
  2. Steinhubl SR. Platelets as mediators of inflammation. Hematol Oncol Clin North Am. 2007;21:115–121
  3. Freedman JE, Loscalzo J. Platelet-monocyte aggregates. Bridging thrombosis and inflammation. Circulation. 2002;105:2130–2132
  4. Gawaz M, Dickfeld T, Bogner C, Fateh-Moghadam S, Neumann FJ. Platelet function in septic multiple organ dysfunction syndrome. Int Care Med. 1997;23:379–385
  5. Janes SL, Kyle PM, Redman C, Goodall AH. Flow cytometric detection of activated platelets in pregnant women prior to the development of pre-eclampsia. Thromb Haemost. 1995;74:1059–1063
  6. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001;66:143–151
  7. Chen M, Geng J-G. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp. 2006;54:75–84
  8. Devaraj S, Glaser N, Griffen S, et al. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes. 2006;55:774–779
  9. Methe H, Kim JO, Kofler S, et al. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation. 2005;111:2654–2661
  10. Patiño R, Ibarra J, Rodriguez A, et al. Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression. Am J Cardiol. 2000;85:1288–1291
  11. The ARIC Investigators . The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129:687–702
  12. Wagenknecht L, Chambless L, Coresh J, et al. Determinants of carotid plaque presence and pathology as measured by magnetic resonance imaging: the Atherosclerosis Risk in Communities (ARIC) (Personal communication).
  13. Catellier DJ, Aleksic N, Folsom AR, Boerwinkle E. Atherosclerosis Risk in Communities (ARIC) Carodit MRI Flow cytometry study of monocyte and platelet markers: intraindividual variability and reliability. Clin Chem. 2008;54:1363–1371
  14. Barnett D, Storie I, Granger V, et al. Standardization of lymphocyte antibody binding capacity: a multicentre study. Clin Lab Haematol. 2000;22:89–96
  15. Brando B, Sommaruga E. Nationwide quality control trial on lymphocyte immunophenotyping and flow cytometer performance in Italy. Cytometry. 1993;14:294–306
  16. Clinical and Laboratory Standards Institute. Enumeration of immunologically defined cell populations by flow cytometry. Approved guideline, second edition. CLSI document H42-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2007.
  17. Gratama JW, Kraan J, Van den Beemd R, et al. Analysis of variation in results of flow cytometric lymphocyte immunophenotyping in a multicenter study. Cytometry. 1997;30:166–177
  18. Owens MA, Vall HG, Hurley AA, Wormsley SB. Validation and quality control of immunophenotyping in clinical flow cytometry. J Immunol Methods. 2000;243:33–50
  19. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Part 2. Clin Chem. 2001;47:418–425
  20. Baecke J, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiologic studies. Am J Clin Nutr. 1982;36:936–942
  21. Kish L. Survey sampling. New York, NY: John Wiley & Sons; 1965;
  22. Cooper RS, Kaufman JS, Ward R. Race and genomics. N Engl J Med. 2003;348:1166–1170
  23. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003;348:1170–1175
  24. Nazmi A, Victora CG. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health. 2007;7:212
  25. Rosamond W, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–e171
  26. Danenberg HD, Kantak N, Grad E, et al. C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy. Eur J Haematol. 2007;78:246–252
  27. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50:159–165
  28. Exner M, Minar E, Miekusch W, et al. Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol. 2006;47:2212–2218
  29. Kumar AP, Reynolds WF. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun. 2005;331:442–451
  30. Stenvinkel P, Rodriguez-Ayala E, Massy ZA, et al. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2006;1:281–287
  31. Fernández-Real JM, Broch M, Richart C, et al. CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab. 2003;88:1780–1784
  32. Morange PE, et al. TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: the PRIME Study. Eur J Hum Genet. 2004;12:1041–1049
  33. Koenig W, Khuseyinova N, Hoffmann MM, et al. CD14 C(-260)→T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. J Am Coll Cardiol. 2002;40:34–42
  34. Risley P, et al. Promoter polymorphism in the endotoxin receptor (CD14) is associated with increased carotid atherosclerosis only in smokers: the Carotid Atherosclerosis progression Study (CAPS). Stroke. 2003;34:600–604
  35. Pasini AF, Anselmi M, Garbin U, et al. Enhanced levels of oxidized low-density lipoprotein prime monocytes to cytokine overproduction via upregulation of CD14 and toll-like receptor 4 in unstable angina. Arterioscler Thromb Vasc Biol. 2007;27:1991–1997
  36. Irie-Sasaki J, Sasaki T, Matsumoto W, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signaling. Nature. 2001;409:349–354
  37. Penninger JM, Irie-Sasaki J, Sasaki T, Oliveira-dos-Santos AJ. CD45: new jobs for an old acquaintance. Nat Immunol. 2001;2:389–396

PII: S0021-9150(08)00783-1

doi: 10.1016/j.atherosclerosis.2008.11.005

Atherosclerosis
Volume 205, Issue 1 , Pages 272-278 , July 2009

Article Tools